- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00349453
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with refractory anemias requiring regular blood transfusions accumulate iron at the rate of approximately 0.5 mg/kg/day, which may lead to serious organ toxicity, e.g. to the heart, liver and endocrine organs. The human body has no active mechanism for the excretion of excess iron. Therefore multiply transfused patients will develop a secondary hemosiderosis, if excess iron is not excreted by a chelating agent. Symptoms of iron-overload occur when body iron stores reach 10-20 g. At higher levels severe, even fatal complications, particularly cardiac failure, may develop.
Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug, but is expensive and must be given by slow subcutaneous or intravenous infusion for 8-12 hours a day during 5-7 days weekly at a dosage of 40-50 mg/kg body weight/day. This often leads to failure of compliance of the patient and therefore to inefficient iron chelation. Further, some patients are hypersensitive to desferrioxamine and others suffer from toxicity, e.g. to the ears or eyes.
Deferiprone (L1; CP20; 1,2 dimethyl-3-hydroxypyrid-4-one) is an orally active iron chelator investigated in various clinical trials since 1987. Dosages of 75 - 100 mg/kg body weight/day of L1 have been considered effective to maintain stable iron balance (urinary iron excretion of 0.5 mg/kg/day) and to reduce serum ferritin levels between 6% and 25% within one year of treatment in iron-overloaded thalassemic patients. There exists long-term experience with patients who have received deferiprone continuously for more than 10 years so far. The main side effects encountered during a deferiprone therapy are arthropathy, gastrointestinal symptoms, headache, and mild zinc deficiency. These adverse reactions are usually reversed on reducing the dose or discontinuing the drug. Except for severe joint symptoms in few patients, most of the subjects in different clinical trials have been able to continue with L1 therapy for a long term. The most severe, but rare complication following administration of deferiprone is agranulocytosis or neutropenia.
A new treatment regimen combining deferiprone with desferrioxamine is currently being investigated in many countries. Preliminary data have demonstrated that the combined use of both drugs is highly active showing an additive or even synergistic effect (significant decrease of serum ferritin and hepatic iron content, increase of urinary iron excretion). This synergism could be explained by the different mode of action of the two drugs. It could be demonstrated that patients who were not sufficiently chelated with desferrioxamine or deferiprone, could achieve a negative iron balance with the combination treatment of both drugs. The combined regimen was generally well tolerated. It has been speculated that the individual toxicity profile of both drugs can be positively influenced by the simultaneous administration of L1 and DFO. The daily treatment with L1 tablets combined with at least twice a week administration of parenteral desferrioxamine is more patient-convenient and therefore may enhance the patient's compliance.
The primary aim of this study is to systematically investigate the long-term safety (toxicity assessment according to CTCAE v3.0) of deferiprone either given alone or in combination with desferrioxamine. Further, in patients agreeing to perform annual SQUID analysis of the liver, the annual change of liver iron concentration (LIC) will be examined for four years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bern, Switzerland, 3014
- Private children's practice
-
St. Gallen, Switzerland, 9006
- Children's Hospital of Eastern Switzerland
-
Zurich, Switzerland, 8032
- University Children's Hospital
-
Zurich, Switzerland, 8091
- University Hospital
-
-
Aargau
-
Aarau, Aargau, Switzerland, 5001
- Cantonal Hospital, Children's Clinic
-
Aarau, Aargau, Switzerland, 5001
- Cantonal Hospital
-
-
Graubünden
-
Chur, Graubünden, Switzerland, 7000
- Cantonal Hospital Graubünden
-
-
Ticino
-
Arzo, Ticino, Switzerland, 6864
- Private Practice
-
Lugano, Ticino, Switzerland, 6900
- Private Practice
-
Lugano, Ticino, Switzerland, 6900
- Regional Hospital
-
Riva San Vitale, Ticino, Switzerland, 6826
- Private Practice
-
-
Wallis
-
Brig, Wallis, Switzerland, 3900
- Private children's practice
-
-
Zurich
-
Oerlikon, Zurich, Switzerland, 8050
- Private Practice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Iron overloaded male or female patients with primary or secondary hemochromatosis
- Age: 4 years and older
- Patients with desferrioxamine toxicity or allergy (e.g. visual or hearing defects, bone abnormalities, reactions at injection site)
- Patients unable or unwilling to comply satisfactorily with regular desferrioxamine administration on 5-7 days/week
- Combination treatment: patients not sufficiently chelated with desferrioxamine or deferiprone monotherapy
- Patients must be willing to undergo routine screening including medical history, physical examination and hematology, biochemistry and other laboratory tests
- Written informed consent
Exclusion Criteria:
- Children under 4 years of age
- Female and male of reproductive age, sexually active but not taking adequate contraceptive precaution
- Woman who are pregnant or breast-feeding
- Patients with HIV
- Patients with active hepatitis requiring treatment
- Patients with severe hepatic failure, cirrhosis
- Patients with neutropenia (neutrophils less than 1.5 exp9/l, MDS: less than 0.5 exp9/l)
- Patients with thrombocytopenia (platelets less than 100 exp9/l, MDS: less than 20 exp9/l)
- Patients with decompensated heart failure (LVEF less than 40% or patients under continuous cardiac medication)
- Patients with severe renal failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deferiprone (L1) monotherapy
|
75 mg/kg body weight daily
50-100 mg/kg body weight daily
|
Experimental: Combination therapy
Deferiprone (L1) and desferrioxamine combination treatment
|
75 mg/kg body weight daily
50-100 mg/kg body weight daily
35-50 mg/kg body weight on 2 or more days per week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Liver Iron Concentration (LIC) by SQUID
Time Frame: Yearly
|
Yearly
|
Long-term safety profile
Time Frame: Long-term
|
Long-term
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum ferritin
Time Frame: At quarterly control visits
|
At quarterly control visits
|
Urinary Iron Excretion (UIE)
Time Frame: At six-monthly control visits
|
At six-monthly control visits
|
Heart iron content (optional) by MRI T2* and MRI SIR
Time Frame: Yearly
|
Yearly
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Petrign FG Töndury, MD
- Principal Investigator: Markus Schmugge Liner, MD, University Children's Hospital, Zurich
Publications and helpful links
General Publications
- Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol. 1998 Jun;101(3):413-5. doi: 10.1046/j.1365-2141.1998.00725.x.
- Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol. 1990 Dec;76(4):550-3. doi: 10.1111/j.1365-2141.1990.tb07915.x.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Iron Metabolism Disorders
- Metabolism, Inborn Errors
- Metal Metabolism, Inborn Errors
- Iron Overload
- Hemochromatosis
- Hemosiderosis
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Siderophores
- Deferoxamine
- Deferiprone
Other Study ID Numbers
- DF-2/CH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemochromatosis
-
Rennes University HospitalCompletedEstimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (HEMOCOEUR)Myocardial Iron Overload | HFE-Associated Hereditary HemochromatosisFrance
-
University Hospital, LilleCompleted
-
Sanquin Research & Blood Bank DivisionsRadboud University Medical Center; Maastricht University Medical Center; Atrium... and other collaboratorsUnknownHereditary HemochromatosisNetherlands
-
Rennes University HospitalCompletedHemochromatosis Type 1France
-
Bond BiosciencesTerminatedHereditary HemochromatosisAustralia
-
Protagonist Therapeutics, Inc.CompletedHereditary HemochromatosisUnited States, Canada
-
Rennes University HospitalMinistry of Health, FranceCompletedGenetic HemochromatosisFrance
-
Novartis PharmaceuticalsCompletedIron Overload | Hereditary HemochromatosisUnited States, Germany, Italy, Australia, Canada, France
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHereditary HemochromatosisUnited States
-
Novartis PharmaceuticalsCompletedHereditary HemochromatosisBelgium, France, Russian Federation, Romania, Slovakia, Spain, Switzerland
Clinical Trials on Deferiprone (L1)
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)TerminatedHeart Diseases | Cardiovascular Diseases | Beta-ThalassemiaUnited States
-
LipomedCompletedHemochromatosisEgypt, Turkey
-
ApoPharmaFood and Drug Administration (FDA)CompletedPantothenate Kinase-Associated NeurodegenerationUnited States, Germany, Italy, United Kingdom
-
Sheba Medical CenterHadassah Medical Organization; Kaplan Medical Center; Tel Aviv Medical Center; Ziv...CompletedMyelodysplastic Syndrome With Low-grade Lesions | Iron Overload Due to Repeated Red Blood Cell TransfusionsIsrael
-
ApoPharmaCompleted
-
ApoPharmaCompletedHepatic ImpairmentUnited States
-
ApoPharmaCompleted
-
ApoPharmaCompleted
-
Consorzio per Valutazioni Biologiche e FarmacologicheEuropean CommissionCompletedChronic Iron OverloadItaly, Cyprus, Egypt
-
ApoPharmaCompletedProlonged QTc IntervalUnited States